Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -The double mutant variant B.1.617 lineage, S:E484Q+L452R (India)
Diagnostic antibodies and antigens for Companion Animal disease testing
● Rabbit
Diagnostic antibodies and antigens for Swine disease testing
Diagnostic antibodies and antigens for Avian disease testing
Diagnostic antibodies and antigens for Multiple animal disease testing
Diagnostic antibodies and antigens for Ruminant disease testing
● Deer
Diagnostic antibodies and antigens for infectious and non-infectious Equine/Horse disease testing
SOCAIL MEDIA
The world is in midst of the COVID-19 pandemic. Recently A new “double mutant” variant of the coronavirus has been detected from samples collected in India. The two mutations (E484Q and L452R mutations) come together in the same virus, may be more infectious or less affected by vaccines.1
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India)
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India), which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.
SARS-COV-2 (2019nCOV) -double mutant variant B.1.617 lineage, S:E484Q+L452R (India) of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) -double mutant variant B.1.617 lineage, S:E484Q+L452R (India)
GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India).
Mutations of Spike protein in SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India)
Two of the spike mutations are at key residues in the RBD (E484Q and L452R), two are in the N-terminal domain (T95I and E154K).2.
| Spike Mutation in SARS-COV-2 (2019nCOV) double mutant variant B.1.617 lineage, S:E484Q+L452R (India) | Spike-S1 Subunit N Terminal | T95I | |
| E154K | Important residues mutation | ||
| Spike-RBD | L452R | Important residues mutation | |
| E484Q | Important residues mutation | ||
| Spike-S1 Subunit | D614G | A popular mutation in different new SARS-CoV-2 lineage | |
| Spike-S2 Subunit | P681R |
Reference
1.Soutik Biswas. ‘Double mutant’: What are the risks of India’s new Covid-19 variant. https://www.bbc.com/news/world-asia-india-56517495.
2.INSACOG. “Genome Sequencing by INSACOG shows variants of concern and a Novel variant in India ” INSACOG, 2021. https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1707177.
